Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor responsein prostate cancer
C. de Aguiar Ferreira, H. K. Potluri, C. Massey, J. J. Grudzinski, A. Carston, N. Clemons, A. S. Thickens, Z. Rosenkrans, C. Choi, A. Pinchuk, O. Kwon, J. J. Jeffery, B. Bednarz, Z. Morris, J. Weichert, , R. Hernandez
This study shows that 225Ac-NM600, an alpha-emitting radiopharmaceutical, enhances anti-tumor responses in prostate cancer by modulating the immune microenvironment.
bioRxiv · Sep 26, 2022 · PreprintImmunology